Bronchitis News and Research

RSS

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

Prime Urgent Care offers enhanced services to better meet the needs of patients

Prime Urgent Care, a walk-in urgent care facility, has long offered fast services and affordable care for residents of the greater Pearland region. Prime Urgent Care is now offering enhanced services to better meet the needs of its patients.

1 Jun 2013

Study: Extended azithromycin therapy may offer significant benefits to COPD patients

Extended use of a common antibiotic may prolong the time between hospitalizations for patients suffering from chronic obstructive pulmonary disease, according to a post-hoc analysis of a multicenter study which compared the hospitalization rates of patients treated with a 12-month course of azithromycin to the rates of those treated with placebo.

22 May 2013

Childhood respiratory infections rather than analgesics usage linked to risk for asthma

A new study conducted by Boston researchers reports that the link between asthma and early childhood use of acetaminophen or ibuprofen may be driven by underlying respiratory infections that prompt the use of these analgesics, rather than the drugs themselves.

21 May 2013

Lung Volume Reduction Coil may play key role in treatment of emphysema, study finds

A small, easily implantable device called the Lung Volume Reduction Coil may play a key role in the treatment of two types of emphysema, according to a study conducted in Europe. Results of the study indicate the beneficial effects of the device persist more than a year after initial treatment.

21 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Private insurers have cost Medicare almost $300 billion more over the life of the program

A study published online today finds that the private insurance companies that participate in Medicare under the Medicare Advantage program and its predecessors have cost the publicly funded program for the elderly and disabled an extra $282.6 billion since 1985, most of it over the past eight years. In 2012 alone, private insurers were overpaid $34.1 billion.

13 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Ozone attacks lung surface fluids, causes severe respiratory problems

Research at Birkbeck, University of London uses world-leading neutron sources at ILL and ISIS to demonstrate ozone attacks on lung surface fluids.

12 Apr 2013

ACOEM provides tools, resources to help employers identify and respond to impact of COPD

Awareness campaign for the workplace provides tools and information on preventing and managing chronic obstructive pulmonary disease - the third leading cause of death in the U.S.

12 Apr 2013

Scientists demonstrate feasibility of using already-approved drugs against pathogens

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses.

11 Apr 2013

Researchers develop new device to battle against secondhand tobacco smoke

Dartmouth researchers have taken an important step in the ongoing battle against secondhand tobacco smoke. They have pioneered the development of a breakthrough device that can immediately detect the presence of secondhand smoke and even third-hand smoke.

25 Mar 2013

Relighting cigarettes related to economic factors, researchers find

In what is believed to be a first of its kind study, a research member at The Cancer Institute of New Jersey and colleagues have found that an accelerating trend of smokers relighting cigarettes is related to economic factors, and the practice has implications for tobacco dependence treatment and policy.

19 Mar 2013

Chronic obstructive pulmonary disease (COPD) inflammatory subtypes: an interview with Dr Vanessa McDonald, University of Newcastle, Australia

COPD is defined as a preventable and treatable disease associated with significant extrapulmonary consequences that may contribute to severity. The pulmonary component of COPD is characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive with an abnormal inflammatory response of the lungs to noxious particles (GOLD Strategy Document). Airflow obstruction in COPD is not highly variable and largely irreversible.

8 Mar 2013

Roundup: N.J. seeks to recover $10M from adult day care centers after Medicaid bills; Ga. panel to implement provider fee picked; Pa.'s adultBasic in limbo after ruling

A state agency that serves as a watchdog over New Jersey government announced Wednesday that it has found improper billing of Medicaid by five adult day care centers and is asking the centers to pay settlements totaling more than $10 million. The state comptroller's office found that centers were charging the state for caring for patients when they did not receive care in some cases and for providing care that was not needed in others.

7 Mar 2013

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin is a broad spectrum penicillin, and in the UK is one of the most frequently used antibiotics. It is commonly used either on its own or, where there are particular concerns about resistance, in combination as Co-amoxiclav (as Amoxicillin-clavulanic acid) which extends its anti-bacterial spectrum.

1 Mar 2013

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA).

23 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013